What is OccuRx?
Established in 2014, OccuRx operates at the intersection of advanced biotechnology and clinical ophthalmology. The company specializes in the development of novel therapeutic strategies designed to mitigate retinal fibrosis, a condition that often leads to vision loss in patients suffering from diabetic retinopathy and other degenerative ocular diseases. By focusing on anti-inflammatory and anti-fibrotic mechanisms, OccuRx has carved out a specialized niche within the biopharmaceutical sector.
The company's market position is bolstered by a robust intellectual property portfolio, which includes a library of chemical entities specifically engineered to target the underlying pathology of fibrotic diseases. This scientific foundation, combined with a strategic focus on high-impact medical outcomes, has allowed OccuRx to maintain a competitive edge in the development of next-generation treatments for complex retinal disorders.
How much funding has OccuRx raised?
OccuRx has raised a total of $21.2M across 2 funding rounds:
Private Equity
$5.2M
Other Financing Round
$16M
Private Equity (2015): $5.2M with participation from Brandon Capital Partners, Medical Research Commercialisation Fund (MRCF), and Uniseed
Other Financing Round (2022): $16M led by Uniseed and Brandon BioCatalyst
Key Investors in OccuRx
Brandon BioCatalyst
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand, dedicated to transforming biomedical research discoveries into medical products that enhance patient outcomes.
Uniseed
Uniseed is a unique commercialization fund that invests in researchers, technologies, and businesses aimed at creating a positive impact on the world through seed capital and expert guidance.
Medical Research Commercialisation Fund (MRCF)
The MRCF specializes in transforming biomedical research discoveries into medical products, collaborating with major superannuation funds and research institutes to support pre-clinical and clinical stage innovations.
What's next for OccuRx?
Looking ahead, the infusion of capital will likely be directed toward scaling clinical operations and refining the regulatory pathway for its lead candidates. As the company moves deeper into the development lifecycle, the focus will shift toward establishing strategic partnerships and preparing for potential commercialization. The ongoing support from its core investor base provides the necessary runway to navigate the complexities of drug development, from pre-clinical validation to human trials. Investors and industry observers will be closely monitoring the company's progress as it seeks to translate its innovative research into tangible clinical benefits for patients worldwide.
See full OccuRx company page
